<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767791</url>
  </required_header>
  <id_info>
    <org_study_id>2015/34</org_study_id>
    <secondary_id>2015-A01988-41</secondary_id>
    <nct_id>NCT02767791</nct_id>
  </id_info>
  <brief_title>Auriculotherapy and Acupuncture's Treatment for Chemotherapy-induced Nausea and Vomiting (CINV)</brief_title>
  <acronym>NVCI</acronym>
  <official_title>Auriculotherapy and Acupuncture's Treatment for Chemotherapy-induced Nausea and Vomiting (CINV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The management of chemotherapy-induced nausea and vomiting (CINV) has evolved in recent years
      and became less frequent. CINV include early (occurring within 24 hours of chemotherapy
      administration) and delayed (occurring within 4 days after chemotherapy) nausea and vomiting.

      Preventive treatment, such as Glucocorticoids, 5-HT3 receptor antagonists and NK1 receptor
      antagonists, are administered according to the classification in 4 grades of expected CINV

        -  Very low: &lt;10% occurrence of CINV;

        -  Low: 10 to 30% occurrence of CINV;

        -  Average: 30 to 90% occurrence of CINV;

        -  High: &gt; 90% occurrence of CINV. These treatments have been the subject of
           recommendations. Despite these available treatments, some patients still complain of
           vomiting, or more frequently nausea and loss of appetite.

      Meanwhile, Chinese acupuncture has proven effective on the prevention of CINV as
      complementary treatment, mainly in the acute phase and to a lesser extent in the delayed
      phase. The most common points are Pericardium 6 (wrist) treated with conventional acupuncture
      needles, electro-acupuncture or acupressure.

      Auriculotherapy (ear acupuncture) has proven effective on nausea of pregnancy and
      postoperative nausea, but, to our knowledge, there are no studies published on the effect of
      auriculotherapy on CINV.

      These complementary treatments have virtually no side effects. In our institution, a simple
      treatment of acupuncture (2 points Pericardium 6 treated) and auriculotherapy (2 auricular
      point treated) is regularly use in patients who present CINV despite preventive treatment and
      most of them are relieved.

      The investigators propose a clinical trial in this population to assess symptoms improvement
      in patients presenting CINV after their first administration of chemotherapy despite adapted
      preventive treatment. Experimental treatment with semi-permanent needles takes place during
      administration of the second session of chemotherapy. CINV are evaluated through the MAT
      score (Multinational Association of Supportive Care in Cancer Antiemesis Tool.
      Http://www.mascc.org/) that measures the frequency and intensity of nausea and vomiting in
      the 24 hours following the session and during the 4 days after administration Chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Digital Scale for nausea</measure>
    <time_frame>1 day</time_frame>
    <description>Digital Scale for nausea (H24 MAT score)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Acupuncture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acupuncture wrist 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Auriculotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Auriculotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Auriuclotherapy and acupuncture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Auriuclotherapy and acupuncture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acupuncture</intervention_name>
    <description>Acupuncture</description>
    <arm_group_label>Acupuncture</arm_group_label>
    <arm_group_label>Auriuclotherapy and acupuncture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Auriculotherapy</intervention_name>
    <description>Auriculotherapy</description>
    <arm_group_label>Auriculotherapy</arm_group_label>
    <arm_group_label>Auriuclotherapy and acupuncture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  out-patient chemotherapy

          -  treated NVIC (nausea vomitting induced by chemotherapy)

        Exclusion Criteria:

          -  prior treatment with acupuncture and or auriculotherapy for NVIC

          -  no conventionnal treatment for NVIC like phytotherapy and homeopathy

          -  radiotherapy (five days before and 5 days after chemotherapy)

          -  MRI in the five days after first visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mireille Michel-Cherqui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Foch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mireille Michel-Cherqui, MD</last_name>
    <phone>+33(0)146252895</phone>
    <email>m.michel-cherqui@hopital-foch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre hopsitalier Emmanuel Rain</name>
      <address>
        <city>Gonesse</city>
        <zip>95500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Huguet</last_name>
      <email>sophuguet@laposte.net</email>
    </contact>
    <investigator>
      <last_name>Sophie Huguet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claude Boiron, MD</last_name>
      <email>claude.boiron@curie.net</email>
    </contact>
    <investigator>
      <last_name>Claude Boiron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre spécilaisé en cancérologie Paris Nord</name>
      <address>
        <city>Sarcelles</city>
        <zip>95200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cyril Laporte, MD</last_name>
      <email>cyril.laporte@free.fr</email>
    </contact>
    <investigator>
      <last_name>Cyril Laporte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mireille Michel-Cherqui</last_name>
      <phone>+33(0)146252985</phone>
      <email>m.michel-cherqui@hopital-foch.org</email>
    </contact>
    <investigator>
      <last_name>Mireille Michel-Cherqui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

